Introduction
diabetes
TYPE 2 DIABETES, TYPE 2 DIABETES, REMISSION, DIABETES
The 2008 Food and Drug Administration (FDA) guidance requiring ascertainment of the cardiovascular safety of new glucose-lowering medications has launched an era in which the vascular implications of diabetes therapies are fundamental considerations in the management of type 2 diabetes (T2DM)[In the recently-reported PREserVing Beta-cell Function in Type 2 Diabetes with Exenatide And InsuLin (PREVAIL) Trial, we demonstrated that 3 glargine-based regimens (glargine alone, glargine with thrice daily meal insulin lispro, and glargine with twice daily administration of the GLP1-RA exenatide) had similar effects on both pancreatic beta-cell function after 8 weeks of treatment (primary outcome) and rates of diabetes remission after 12-weeks washout [